FIGURE 2.

Progression‐free survival associated with regorafenib monotherapy and regorafenib combined with a PD‐1 antibody in all enrolled patients (A), male patients (B), female patients (C), patients with liver metastasis (D), and in patients without liver metastasis (E). Progression‐free survival associated with regorafenib combined with a PD‐1 antibody (F) and regorafenib monotherapy (G) in patients without a history of liver metastasis and in patients with liver involvement history but without active liver metastasis at the time of treatment. Progression‐free survival associated with regorafenib monotherapy (H) and regorafenib combined with a PD‐1 antibody (I) grouped by liver and lung metastasis